Coherus Oncology (CHRS) Accumulated Expenses (2013 - 2026)

Coherus Oncology has disclosed Accumulated Expenses across 14 years of filings, most recently posting $15.2 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $15.2 million, down 23.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.2 million (down 23.8% YoY), and the FY2025 annual result was $14.6 million, down 75.82% from the prior year.
• Accumulated Expenses came in at $15.2 million for Q1 2026 at Coherus Oncology, up from $14.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $67.1 million in Q3 2023 to a low of $3.6 million in Q2 2024.
• The 5-year median for Accumulated Expenses is $15.8 million (2024), against an average of $24.2 million.
• Across the five-year window, Accumulated Expenses surged 738.11% in 2023 and tumbled 91.43% in 2024, its largest moves.
• Coherus Oncology's Accumulated Expenses stood at $5.0 million in 2022, then soared by 738.11% to $42.0 million in 2023, then surged by 43.44% to $60.3 million in 2024, then sank by 75.82% to $14.6 million in 2025, then climbed by 4.27% to $15.2 million in 2026.
• The last three Accumulated Expenses figures came in at $15.2 million (Q1 2026), $14.6 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.